MARK CANNON: Open Payments
NPI 1720169295 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,377 in 253 payments from 14 companies in 2025. Trend: 2023 $2,451 · 2024 $3,270 · 2025 $3,377
Food & beverage: $3,377
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 45 | $529 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $410 |
| ABBVIE INC. | 41 | $397 |
| Alkermes, Inc. | 20 | $363 |
| Otsuka America Pharmaceutical, Inc. | 21 | $327 |
| Neurocrine BioSciences, Inc. | 15 | $323 |
| Vanda Pharmaceuticals Inc. | 34 | $320 |
| Axsome Therapeutics, Inc. | 16 | $211 |
| Janssen Pharmaceuticals, Inc | 10 | $200 |
| Teva Pharmaceuticals USA, Inc. | 17 | $173 |
Products named: COBENFY, CAPLYTA, VRAYLAR, INGREZZA, ARISTADA, HETLIOZ, REXULTI, Auvelity.
Industry payments across MO — which companies pay providers there.
